Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 150Lung Neoplasms 58Pancreatic Neoplasms 34Neoplasms 20Neoplasm Metastasis 15Breast Neoplasms 15Adenocarcinoma of Lung 15Brain Neoplasms 14Adenocarcinoma, Bronchiolo-Alveolar 13Glioblastoma 12Non-Squamous Non-Small Cell Lung Cancer 11Head and Neck Neoplasms 11Gliosarcoma 11Squamous Cell Carcinoma of Head and Neck 10Carcinoma, Hepatocellular 10Colorectal Neoplasms 8Carcinoma, Renal Cell 8Esophageal Neoplasms 6Urinary Bladder Neoplasms 5Gallbladder Neoplasms 5Colonic Neoplasms 5Central Nervous System Neoplasms 5Carcinoma, Squamous Cell 5Adenocarcinoma 5Rectal Neoplasms 4Prostatic Neoplasms 4Ovarian Neoplasms 4Liver Neoplasms 4Kidney Neoplasms 4Fallopian Tube Neoplasms 4

Interventions

atezolizumab 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1GSK 1363089 1Erlotinib Hydrochloride 1Disulfides 1Contrast Media 1Biopsy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Papillary renal cell carcinoma, sporadic × Erlotinib Hydrochloride × Clear all
NCT04981509 2026-06-03

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
65 enrolled
Genitourinary

Hereditary leiomyomatosis and renal cell cancer, Papillary renal cell carcinoma, sporadic, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡